Loading
A phase 1/2 trial of Osimertinib in non-small-cell lung cancer, run by Genprex, Inc., now recruiting.
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib is a phase 1/2 interventional study registered as NCT04486833 by Genprex, Inc., with 158 participants planned, started 2021-09-03 and due to reach its primary completion in 2028-03. Interventions recorded: quaratusugene ozeplasmid, osimertinib and Platinum-Based Chemotherapy.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.